Telomere length is an independent prognostic marker in MDS but not in de novo AML

Telomere length is an independent prognostic marker in MDS but not in de novo AML

Telomere dysfunction is implicated in the generation of large‐scale genomic rearrangements that drive progression to malignancy. In this study we used high‐resolution single telomere length analysis (STELA) to examine the potential role of telomere dysfunction in 80 myelodysplastic syndrome (MDS) an...

Szczegółowa specyfikacja

Opis bibliograficzny
Główni autorzy:	Williams, J, Heppel, N, Britt-Compton, B, Grimstead, J, Jones, R, Tauro, S, Bowen, D, Knapper, S, Groves, M, Hills, R, Pepper, C, Baird, D, Fegan, C
Format:	Journal article
Język:	English
Wydane:	Wiley 2017

Podobne zapisy

Telomere length is a critical determinant for survival in multiple myeloma
od: Hyatt, S, i wsp.
Wydane: (2017)

Maintenance of telomere length in AML
od: Peter M. Lansdorp
Wydane: (2017-11-01)

Short Dysfunctional Telomere is Highly Predictive of Dismal Outcome in MDS but Not in AML Patients
od: Nadia El Menshawy, i wsp.
Wydane: (2020-07-01)

Inherited predisposition to MDS/AML
od: Ana Rio Machin, i wsp.
Wydane: (2018-06-01)

Telomerase activity and telomere length in AML-M3 patients
od: Hamidollah Ghaffari, i wsp.
Wydane: (2009-04-01)

Telomerase activity and telomere length in AML-M3 patients
od: Hamidollah Ghaffari, i wsp.
Wydane: (2009-06-01)

T cell memory revisited using single telomere length analysis
od: Laureline Roger, i wsp.
Wydane: (2023-09-01)

PATHWAY-DIRECTED THERAPY APPROACH IN PEDIATRIC MDS AND AML
od: Barbara De Moerloose
Wydane: (2023-12-01)

Gene expression profiling in MDS and AML: potential and future avenues.
od: Theilgaard-Mönch, K, i wsp.
Wydane: (2011)

Psychotropic Drug Use in Acute Myeloid Leukaemia (AML) and Myelodysplastic Syndrome (MDS): A Danish Nationwide Matched Cohort Study of 2404 AML and 1307 MDS Patients
od: Jensen O, i wsp.
Wydane: (2022-02-01)

AML associated with previous cytotoxic therapy, MDS or myeloproliferative disorders: results from the MRC's 9th AML trial.
od: Hoyle, C, i wsp.
Wydane: (1989)

Presence but not number of secondary type mutations influences outcome in de novo AML without MDS‐associated or recurring cytogenetic abnormalities
od: Olga K. Weinberg, i wsp.
Wydane: (2023-08-01)

Transformation of myelodysplastic syndrome (MDS) to acute myeloid leukaemia (AML)
od: Goh, Chermaine Yu Zhen
Wydane: (2021)

p53 biology and reactivation for improved therapy in MDS and AML
od: Joanna E. Zawacka
Wydane: (2024-03-01)

P577: 20% BLAST CRITERIA FOR DIAGNOSING AML/MDS: IS IT TIME TO MOVE BEYOND?
od: V. Sheth, i wsp.
Wydane: (2022-06-01)

P739: THE EPI-GENOMIC LANDSCAPE OF MONOSOMY 7 IN ADULT MDS/AML
od: A. G. Lema Fernandez, i wsp.
Wydane: (2022-06-01)

PERFORMANCE OF CYTOGENETIC TESTS IN AML AND MDS SAMPLES PROCESSED IN A REMOTE LABORATORY IN BRAZIL
od: A Amaro, i wsp.
Wydane: (2024-10-01)

Investigating resistance to 5-Azacytidine and Venetoclax in PDX models of MDS/AML
od: Petra Bašová, i wsp.
Wydane: (2025-01-01)

Paclitaxel Induced MDS and AML: A Case Report and Literature Review
od: Udit Bhaskar Bhatnagar, i wsp.
Wydane: (2016-01-01)

Rewriting the rules for care of MDS and AML patients in the time of COVID-19
od: Azra Raza, i wsp.
Wydane: (2020-01-01)

The complex genetic landscape of familial MDS and AML reveals pathogenic germline variants
od: Ana Rio-Machin, i wsp.
Wydane: (2020-02-01)

Biglycan as a mediator of proinflammatory response and target for MDS and sAML therapy
od: Christoforos K. Vaxevanis, i wsp.
Wydane: (2023-12-01)

Interpretation of the 5th edition of the WHO classification of haematolymphoid tumours on MDS and AML
od: YE Xiangjun, LU Xingguo
Wydane: (2023-10-01)

PB1793: NEUTROPHIL TO LYMPHOCYTE RATIO AS A PROGNOSTIC FACTOR IN AML AND MDS
od: V. Van Oorschot, i wsp.
Wydane: (2022-06-01)

Reciprocal regulation of TWIST1 and OGT determines the decitabine efficacy in MDS/AML
od: Hongjiao Li, i wsp.
Wydane: (2023-09-01)

Polyclonal evolution of Fanconi anemia to MDS and AML revealed at single cell resolution
od: Lixian Chang, i wsp.
Wydane: (2022-09-01)

Generalist in allogeneic hematopoietic stem cell transplantation for MDS or AML: Epigenetic therapy
od: Guancui Yang, i wsp.
Wydane: (2022-10-01)

Overexpression of IL-1 receptor accessory protein in stem and progenitor cells and outcome correlation in AML and MDS.
od: Barreyro, L, i wsp.
Wydane: (2012)

Telomere length in myelodysplastic syndromes.
od: Boultwood, J, i wsp.
Wydane: (1997)

The development of pevonedistat in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML): hope or hype?
od: Anson Snow, i wsp.
Wydane: (2022-07-01)

Role of GFI1 in Epigenetic Regulation of MDS and AML Pathogenesis: Mechanisms and Therapeutic Implications
od: Tarik Möröy, i wsp.
Wydane: (2019-08-01)

Cohesin mutations alter DNA damage repair and chromatin structure and create therapeutic vulnerabilities in MDS/AML
od: Zuzana Tothova, i wsp.
Wydane: (2021-02-01)

TELOMERE LENGTH AND ATHEROSCLEROSIS
od: O. M. Drapkina, i wsp.
Wydane: (2016-09-01)

THREE CASES OF TP53 BIALLELIC-MUTATED AML/MDS BRIDGED TO ALLO-HSCT BY AZA/VEN THERAPY
od: T. Ueda, i wsp.
Wydane: (2024-01-01)

A STAT3 DEGRADER DEMONSTRATES PRE-CLINICAL EFFICACY IN VENETOCLAX RESISTANT MDS & AML
od: A. Shastri, i wsp.
Wydane: (2024-01-01)

P694: RISK ASSESSMENT ACCORDING TO IPSS-M IS SUPERIOR TO AML ELN 2022 RISK CLASSIFICATION IN MDS/AML PATIENTS DEFINED BY ICC – IS AN INCLUSION INTO AML TRIALS JUSTIFIED?
od: Sandra Huber, i wsp.
Wydane: (2023-08-01)

Dysregulated innate immune signaling cooperates with RUNX1 mutations to transform an MDS-like disease to AML
od: Laura Barreyro, i wsp.
Wydane: (2024-06-01)

Patients with spontaneous remission of high-risk MDS and AML show persistent preleukemic clonal hematopoiesis
od: Victoria V. Grunwald, i wsp.
Wydane: (2019-09-01)

Integrated genetic, epigenetic, and immune landscape of mutant AML and higher risk MDS treated with azacitidine
od: Amer M. Zeidan, i wsp.
Wydane: (2024-06-01)

Industry’s role in HIV, hepatitis B, and hepatitis C exclusion in AML and MDS clinical trials
od: Tahsin Anwar, i wsp.
Wydane: (2023-12-01)